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Heterologous priming with the ChAdOx1 nCoV-19 vector vac-
cine followed by boosting with a messenger RNA vaccine 
(BNT162b2 or mRNA-1273) is currently recommended in 
Germany, although data on immunogenicity and reactogenic-
ity are not available. In this observational study we show that, 
in healthy adult individuals (n = 96), the heterologous vaccine 
regimen induced spike-specific IgG, neutralizing antibod-
ies and spike-specific CD4 T cells, the levels of which which 
were significantly higher than after homologous vector vac-
cine boost (n = 55) and higher or comparable in magnitude 
to homologous mRNA vaccine regimens (n = 62). Moreover, 
spike-specific CD8 T cell levels after heterologous vaccina-
tion were significantly higher than after both homologous 
regimens. Spike-specific T cells were predominantly polyfunc-
tional with largely overlapping cytokine-producing pheno-
types in all three regimens. Recipients of both the homologous 
vector regimen and the heterologous vector/mRNA combina-
tion reported greater reactogenicity following the priming 
vector vaccination, whereas heterologous boosting was well 
tolerated and comparable to homologous mRNA boosting. 
Taken together, heterologous vector/mRNA boosting induces 
strong humoral and cellular immune responses with accept-
able reactogenicity profiles.
Among the currently authorized COVID-19 vaccines, the 
ChAdOx1 nCoV-19 adenovirus-based vector vaccine (ChAdOx1) 
and the two mRNA vaccines (BNT162b2 and mRNA-1273) have 
been the most widely used. Both vaccine types are immunogenic 
and have shown remarkable efficacy in preventing COVID-19 dis-
ease1–3. In March 2021, administration of the ChAdOx1 vaccine 
was temporarily suspended in Germany due to the occurrence of 
life-threatening cerebral venous thrombosis and thrombocytope-
nia, primarily in younger women4,5. This resulted in revised recom-
mendations for secondary vaccination of all individuals who had 
received the first dose of the vaccine6. Individuals above the age of 
60 years are recommended to complete vaccination with the vec-
tor vaccine, whereas heterologous boosting with an mRNA vaccine 
is recommended in those <60 years, with the option to voluntarily 
remain on a homologous vector regimen6. Comparative analy-
ses of immunogenicity between the authorized vaccine regimens 
are scarce, and knowledge on immunity and reactogenicity after 
heterologous vaccination is currently limited. We have found that 
priming with the ChAdOx1 vaccine showed a stronger induction of 
spike-specific T cell responses as compared to mRNA priming, while 
antibody responses were more pronounced after mRNA priming7. 
We hypothesized that differences among the vaccine types after 
priming may influence cellular and humoral immunity following 
secondary vaccination. We therefore prospectively enrolled three 
groups of individuals to study the immunogenicity and reactogenic-
ity of a heterologous vector/mRNA prime–booster regimen in com-
parison to the standard homologous regimens. A detailed analysis 
of spike-specific IgG levels and neutralizing antibody activity was 
performed. In addition, spike-specific CD4 and CD8 T cells were 
characterized using flow cytometry. Adverse events within the first 
week after the priming and booster doses were self-reported based 
on a standardized questionnaire.
A total of 216 immunocompetent individuals, primarily compris-
ing employees, were prospectively enrolled at Saarland University 
Medical Center before secondary vaccination with the authorized 
vaccines ChAdOx1 nCoV-19, BNT162b2 or mRNA-1273 (Methods). 
Ninety-seven study participants received heterologous vaccination 
with the ChAdOx1 vector and mRNA booster (vector/mRNA), 
whereas 55 and 64 received homologous regimens with vector or 
mRNA vaccine, respectively (vector/vector and mRNA/mRNA; 
Extended Data Fig. 1). As per guidelines, the time between pri-
mary and secondary vaccination was shorter for mRNA-primed 
(4.3 ± 1.1 weeks) than for vector-primed individuals, with no dif-
ference between vector-based heterologous (11.2 ± 1.3 weeks) and 
homologous regimens (10.8 ± 1.4 weeks). Blood samples were 
drawn at a median of 14 (interquartile range (IQR) = 2) days 
after vaccination. Although all individuals had no known history 
of SARS-CoV-2 infection, three tested positive for SARS-CoV-2 
nucleocapsid (N)-specific IgG and were excluded from further anal-
yses. The groups had similar gender distribution. However, individ-
uals on the homologous vector regimen were slightly older than the 
two other groups, who were of similar age (Extended Data Fig. 2). 
Leukocyte counts, including granulocytes, monocytes and lympho-
cytes, as well as major lymphocyte subpopulations such as CD4 and 
CD8 T cells, and B cells, did not differ between the groups. This also 
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held true for plasmablasts, which were identified as CD38-positive 
cells among IgD–CD27+ CD19-positive switched-memory B cells 
(Extended Data Fig. 2).
Spike-specific IgGs were induced in 212/213 individuals after 
vaccination. IgG levels after heterologous vaccination and homolo-
gous mRNA vaccination were similar (3,630 (IQR = 3721) and 4,932 
(IQR = 4,239) BAU ml–1, respectively), whereas levels after homolo-
gous vector vaccination were significantly lower (404 (IQR = 510) 
BAU ml–1, P < 0.0001, two-sided Kruskal–Wallis test with Dunn´s 
multiple comparisons post test; Fig. 1a). This difference was also 
observed for neutralizing antibodies, which were quantified by a sur-
rogate neutralization test. While the majority of individuals in the 
vector/mRNA and mRNA/mRNA groups had 100% inhibitory activ-
ity, this was significantly lower in the vector/vector group (Fig. 1b).
In the analysis of vaccine-induced T cell responses, overlap-
ping peptide pools derived from the spike protein were used to 
stimulate whole-blood samples (Methods). Spike-specific CD4 and 
CD8 T cells were identified using flow cytometry by induction of 
CD69 and the cytokines interferon (IFN)-γ, tumor necrosis factor 
(TNF)-α and interleukin (IL)-2. The gating strategy and representa-
tive contour plots of cytokine-positive CD4 and CD8 T cells from a 
37-year-old woman following heterologous vaccination are shown 
in Extended Data Fig. 3. Both the heterologous vector/mRNA and 
homologous mRNA/mRNA regimen led to a marked induction of 
spike-specific, IFN-γ-producing CD4 T cells with median percent-
ages of 0.17 (IQR = 0.13%) and 0.16 (IQR = 0.19%), respectively, 
whereas CD4 T cell levels following homologous vector/vector vac-
cination were significantly lower (median 0.04% (IQR = 0.04%), 
each P = 0.0001; Fig. 1c). Interestingly, heterologous mRNA boost-
ing in vector-primed individuals induced the highest percentages of 
spike-specific IFN-γ-producing CD8 T cells (0.28% (IQR = 0.54%)), 
which were not only more pronounced than after homologous vector 
boosting (vector/vector, 0.04% (IQR = 0.08%)) but also higher than 
for the mRNA/mRNA regimen (0.06% (IQR = 0.19)%, P < 0.0001; 
Fig. 1c). Staphylococcus aureus enterotoxin B (SEB)-reactive CD4 or 
CD8 T cell levels did not differ between groups (Fig. 1d). As with 
IFN-γ-producing CD4 and CD8 T cells, similar between-group 
differences were found for spike-specific CD4 T cells producing 
TNF-α or IL-2, and for spike-specific CD8 T cells producing TNF-α 
(Extended Data Fig. 4). Because CD8 T cells generally produce less 
IL-2, differences were less pronounced for IL-2-producing CD8 
T cells. Finally, between-group differences were similar if CD4 or 
CD8 T cells producing any of the three cytokines were considered 
after Boolean gating (Extended Data Fig. 4).
An overview summarizing correlations between plasmablasts and 
spike-specific IgG and their neutralizing activity, and spike-specific 
CD4 and CD8 T cells, is shown in Fig. 1e and Supplementary Table 1. 
As expected, IgG levels showed a significant correlation with 
neutralizing activity in all three groups. A strong correlation was 
also found between spike-specific CD4 and CD8 T cell levels. In 
line with the role of CD4 T cells in supporting antibody production, 
CD4 T cells correlated with IgG levels in both the vector/vector and 
vector/mRNA groups. In the mRNA/mRNA group, antibody levels 
and neutralizing activity were found to correlate with CD8 T cell 
levels; whether this reflects a causal relationship or similar induc-
tion kinetics is currently unknown.
In addition to quantitative analysis of spike-specific CD4 and 
CD8 T cells, we also characterized the cytokine profiles of IFN-γ, 
IL-2 and TNF-α at the single-cell level. Based on the gating strategy 
shown in Extended Data Fig. 5, seven subpopulations—including 
multifunctional T cells producing all three cytokines—could be dis-
tinguished. When analyzed across all three participant groups, the 
majority of spike-specific CD4 T cells (42.5%) were multifunctional. 
In contrast, the dominant population among CD8 T cells consisted 
of dual-positive cells producing IFN-γ and TNF-α (47.3%), fol-
lowed by 30.6% IFN-γ single-positive cells (Extended Data Fig. 5). 
The distribution of cytokine-producing cells showed significant dif-
ferences between the three participant groups, which held true for 
both spike-specific CD4 and CD8 T cells (Fig. 1f). Given the par-
ticular ability of the vector vaccine to induce spike-specific T cells 
during priming7, it is notable that the two vector-primed groups 
had the highest percentage of polyfunctional CD4 T cells irrespec-
tive of the boosting vaccine. This also held true for the dominant 
fraction of CD8 T cells coproducing IFN-γ and TNF-α. In contrast, 
SEB-reactive cytokine profiles among CD4 and CD8 T cells were 
similar in all vaccine groups (Extended Data Fig. 6).
Finally, local and systemic adverse events within the first week 
after primary and secondary vaccination were recorded using a ques-
tionnaire (Fig. 2a). Local reactions, such as pain at the injection site 
and swelling, were similar after priming with the vector and mRNA 
vaccines (Fig. 2b). However, participants reported significantly 
more systemic adverse events, including fever, chills, gastrointestinal 
events, headache, fatigue, myalgia or arthralgia, after the vector vac-
cine; participants also reported more frequent use of antipyretic drugs 
(Fig. 2c). When comparing reactogenicity after secondary vaccina-
tion, both local and systemic events were markedly less frequent in 
vector-primed individuals after the second vector booster. Boosting 
with an mRNA vaccine was less well tolerated in both vector- and 
mRNA-primed individuals, and the spectrum of local and systemic 
adverse events was very similar for both groups. Individual percep-
tion after the first or the second dose appears to be determined by 
the severity of the priming vector vaccine, as recipients of both the 
homologous vector and the heterologous vector/mRNA regimen 
were most affected after the first vaccination (Fig. 2d).
Mixing different vaccine types in heterologous regimens has 
already been deployed in previous vaccine studies. Examples include 
Fig. 1 | Immune responses against the SARS-CoV-2 spike protein after vaccination with homologous and heterologous prime–booster regimens. 
Immune responses were compared between individuals who received either homologous ChAdOx1 nCoV-19 vector/vector vaccination (n = 55), 
heterologous ChAdOx1 nCoV-19 vector/mRNA vaccination (n = 96) or homologous mRNA/mRNA vaccination (n = 62). a,b, Spike-specific IgG levels (a) 
and neutralizing antibodies (ab) (b) were quantified by ELISA and a surrogate neutralization assay. c,d, Percentages of SARS-CoV-2 spike-specific (c) 
and SEB-reactive (d) CD4 and CD8 T cells were determined after antigen-specific stimulation of whole-blood samples, followed by intracellular cytokine 
analysis using flow cytometry. Reactive cells were identified by coexpression of CD69 and IFN-γ among CD4 or CD8 T cells and subtraction of background 
reactivity of respective negative controls. e, Correlations between spike-specific T cell levels, antibody responses and numbers of plasmablasts. f, Cytokine 
expression profiles of spike-specific CD4 and CD8 T cells in all individuals showing single or combined expression of IFN-γ, IL-2 and TNF-α (gating 
strategy shown in Extended Data Fig. 5). a–d, Bars represent medians with IQR. Individuals who received the mRNA-1273 vaccine are indicated in gray  
(1x vector/mRNA, 9x mRNA/mRNA). Differences between groups were calculated using a two-sided Kruskal–Wallis test with Dunn´s multiple 
comparisons post test. e, Correlation coefficients (r) were analyzed according to two-tailed Spearman (Supplementary Table 1). f, Bars represent means 
and standard deviation; ordinary one-way ANOVA tests were performed. a,b, Dotted lines indicate detection limits (DL) for antibodies, indicating  
negative, intermediate and positive levels or levels of inhibition, respectively, per the manufacturer’s instructions. c,d, Dotted lines indicate detection  
limits for SARS-CoV-2-specific CD4 T cells. f, Analysis was restricted to samples with ≥30 cytokine-positive T cells (n = 31 (CD4) and n = 15 (CD8)  
for vector/vector, n = 89 and n = 73 for vector/mRNA and n = 58 and n = 24 for mRNA/mRNA).
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Fig. 2 | Reactogenicity after primary and secondary vaccination with homologous and heterologous prime–booster regimens. a–c, Reactogenicity 
within the first week after priming and after the booster dose was self-reported based on a standardized questionnaire, and was analyzed after the first 
vaccination with either vector (V, n = 150) or mRNA vaccine (mRNA, n = 48), and after the second vaccination with homologous (V/V, n = 54; mRNA/
mRNA, n = 48) and heterologous (V/mRNA, n = 95) vaccine regimens with respect to local/systemic reactions in general (a), stratified for local (b) and 
various systemic adverse events (c). d, Individual perception of which of the two vaccinations had the greater affect. Comparisons between groups were 
performed using the X² test. GI, gastrointestinal.
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experimental vaccines towards human immunodeficiency virus8 
and malaria9, and the authorized vector vaccine against Ebola virus 
disease10. Although no data were available on the immunogenicity 
and efficacy of heterologous strategies among authorized COVID-
19 vaccines, this raised confidence in recommending a heterologous 
mRNA booster vaccination in ChAdOx1 vector-primed individuals 
after recognition of severe adverse events of cerebral venous throm-
bosis4,5. We show that the heterologous regimen led to a strong 
induction of both antibodies and T cells. IgG levels were similar in 
magnitude to those following homologous mRNA vaccination, and 
approximately tenfold higher than those after homologous vector 
vaccination. Similar differences were found for vaccine-induced 
CD4 T cells, while neutralizing antibody activity and spike-specific 
CD8 T cell numbers were even more pronounced after heterolo-
gous vaccination. Similar results were recently reported in mice11. 
Despite the strong ability of the ChAdOx1 vaccine to induce T cells 
after priming7, the strikingly lower immunogenicity following the 
homologous ChAdOx1 booster dose affected both antibodies and 
T cells. This may result from neutralizing immunity towards the 
vector backbone induced after the first vaccine dose12, which could 
have rendered secondary vaccination less efficient. Our results show 
that both vector-primed antibodies and T cells are particularly well 
induced when combined with mRNA as the secondary vaccine.
Although the heterologous group reported more pronounced 
systemic adverse events after vector priming, boosting with the 
mRNA vaccine was less severe and well tolerated and the spectrum 
of both local and systemic adverse events was comparable to the 
homologous mRNA regimens. A recent study also showed strong 
induction of humoral immunity after a second dose of BNT162b2 
in individuals primed with the vector vaccine. Similar to our study, 
the booster dose was given 8–12 weeks after priming13. Although 
there was no direct comparison with homologous regimens, the 
reactogenicity profile was also rather moderate13. This contrasts 
with reactogenicity data from the Com-COV trial, where adverse 
events in the heterologous regimens were more severe than in 
homologous groups14. Whether this was due to the shorter interval 
between priming and boosting (4 versus 9–12 weeks) and whether 
this affects immunogenicity await further study. Our observa-
tional study based on a convenience cohort is limited by the 
fact that direct comparison of immunity in the same individuals 
after the first vaccine dose was not possible, because data after pri-
mary vaccination were available for only a subset of the mRNA/
mRNA group and the majority of vector-primed individuals 
were enrolled after primary vaccination. However, in a separate 
group of vector-primed individuals, antibody levels were higher 
following mRNA priming whereas T cell levels were higher after 
vector priming7. Another limitation of our study is that most mRNA 
vaccine recipients received BNT162b2, although results appear 
similar for mRNA-1273. In addition, the homologous ChAdOx1 
nCoV-19 vaccine group was slightly older due to age-related dif-
ferences in general recommendations. However, because a sub-
group analysis of age-matched individuals gave the same results 
(Extended Data Fig. 7), we speculate that the difference in age 
is unlikely to account for the reduced immune responses in this 
group. Although we show strong neutralizing activity in a surro-
gate assay, neutralizing activity towards wild-type virus or vari-
ants of concern was not specifically assessed. Finally, no vaccine 
efficacy data are available to inform on protection from infection 
or disease. While this awaits further study, immune-based corre-
lates of protection will be important in estimating the efficacy of 
vaccines and vaccine combinations15. Neutralizing antibodies have 
been discussed as promising candidates15,16 that mirror the efficacy 
of vector and mRNA regimens1–3. Because immunogenicity after 
heterologous vaccination is comparable—or in part superior—to 
homologous mRNA regimens, it will be interesting to see whether 
this translates into similar efficacy.
Although vaccine development focuses on antibodies due to their 
ability to confer sterilizing immunity, T cells are important in medi-
ating protection from severe disease17 and may be less affected by 
virus variants18. The T cell data from this and similar studies could 
influence the development of future vaccine strategies, including 
how to improve vaccine-induced T cell immunity and protection 
from severe disease among vulnerable groups of immunocompro-
mised patients.
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Methods
Study design and subjects. A convenience cohort of immunocompetent 
individuals with no known history of SARS-CoV-2 infection was invited to 
participate in this observational study, and were enrolled before secondary 
vaccination and after primary vaccination with either ChAdOx1 nCoV-19 or 
one of the mRNA vaccines (BNT162b2 or mRNA-1273). The majority of study 
participants were PCR tested on a regular basis due to their occupational activity  
in a hospital setting. This study was not a randomized clinical trial, but was  
based on the revised recommendations that were issued in Germany on 1 April 
2021 for secondary vaccination of all individuals who had received the first  
dose of the ChAdOx1 nCoV-19 vector vaccine6. The study did not influence the 
decision on vaccine regimens: decisions were exclusively assigned based on  
current recommendations6. Blood sampling for immunological analyses was 
performed after having received a homologous vaccine regimen comprising  
either ChAdOx1 nCoV-19 or one of the mRNA vaccines (BNT162b2 or mRNA-
1273), or a heterologous vaccine regimen comprising a ChAdOx1 nCoV-19 
priming dose followed by secondary vaccination with an mRNA vaccine.  
The time interval between the first and second dose was determined as per  
national guidelines6 and varied from 3 to 6 weeks for the homologous mRNA 
regimens to 9–12 weeks for the homologous ChAdOx1 nCoV-19 and the 
heterologous ChAdOx1 nCoV-19/mRNA regimena19. Lymphocyte subpopulations, 
as well as vaccine-induced SARS-CoV-2-specific humoral and cellular immunity, 
were determined from heparinized whole blood 14 days after the second vaccine 
dose, with an interval of 13–18 days tolerated. Local and systemic adverse events 
within 7 days after the first and second vaccination were self-reported using a 
standardized questionnaire. Reactogenicity after the second dose was collected 
prospectively in all cases using a standardized questionnaire. Reactogenicity  
data after the first dose were collected retrospectively in the majority of cases,  
but all participants felt confident in recalling adverse events at the time of 
enrollment into the study.
Vaccinations were performed between 10 January and 8 April 2021. All 
individuals in the vector-primed group had their first vaccination before 1 April, 
because primary vector vaccination was suspended at Saarland University Medical 
Center thereafter. Immunity after secondary vaccination in 28 individuals in the 
mRNA/mRNA group was tested before 1 April. Testing in these individuals was 
offered as a service to those working in intensive care units on a voluntary basis as 
part of routine diagnostics. All provided written informed consent to have their 
immunogenicity and reactogenicity data included as control group in this study. 
Moreover, 32 individuals (20 mRNA and 12 vector primed) represent a subgroup of 
immunocompetent controls enrolled in a separate observational study (SaarTxVac 
study). Their results following the induction of humoral and cellular immunity 
after the first vaccination are part of a separate manuscript7 that addresses the 
induction of humoral and cellular immunity after vector and mRNA priming 
in immunocompetent individuals and transplant recipients. The results of their 
immune response after secondary vaccination (18 cases tested before and 14 after 
1 April) are included in the present study. The study was approved by the ethics 
committee of the Ärztekammer des Saarlandes (no. 76/20), and all individuals gave 
written informed consent.
Quantification of lymphocyte populations and plasmablasts. T cells, B cells  
and plasmablasts were quantified from 100 µl of heparinized whole blood as 
described previously20 using monoclonal antibodies towards CD3 (clone SK7,  
final dilution 1:25), CD19 (clone HIB19, 1:40), CD27 (clone L128, 1:200), 
CD38 (clone HB7, 1:20) and IgD (clone IA6-2, 1:33.3). T and B cells were 
identified among total lymphocytes by expression of CD3 and CD19, 
respectively. Plasmablasts were characterized by expression of CD38 among 
IgD–CD27+ CD19-positive switched-memory B cells. CD4 and CD8 T cells 
were quantified after additional staining of CD4 (clone SK3, 1:100) and CD8 
(clone RPA-T8). Antibodies used are listed in Supplementary Table 2. Analysis 
was performed on a BD FACSLyric flow-cytometer and BD FACSuite software 
v.1.4.0.7047, followed by data analysis using FlowJo software 10.6.2. The gating 
strategy is shown in Supplementary Fig. 1. Absolute lymphocyte numbers were 
calculated based on differential blood counts.
Quantification of vaccine-induced SARS-CoV-2-specific T cells. SARS-CoV-
2-specific T cells were determined from heparinized whole blood after 6-h 
stimulation with overlapping peptides spanning the SARS-CoV-2 spike protein 
(N-terminal receptor binding domain and C-terminal portion including the 
transmembrane domain, each peptide 2 µg ml–1; JPT) as described previously20. 
Stimulations with 0.64% DMSO and 2.5 μg ml–1 of SEB (Sigma) served as negative 
and positive controls, respectively. All stimulations were carried out in the presence 
of costimulatory antibodies against CD28 and CD49d (clones L293 and 9F10, 
1 μg ml–1 each). Immunostaining was performed using anti-CD4 (clone SK3, 
1:33.3), anti-CD8 (clone SK1, 1:12.5), anti-CD69 (clone L78, 1:33.3), anti-IFN-γ 
(clone 4 S.B3, 1:100), anti-IL-2 (clone MQ1-17H12, 1:12.5) and anti-TNF-α 
(clone MAb11, 1:20), and analyzed using flow cytometry (BD FACS Canto II, 
including BD FACSdiva software 6.1.3). Antibodies are listed in Supplementary 
Table 2. SARS-CoV-2-reactive CD4 or CD8 T cells were identified as activated 
CD69-positive T cells producing IFN-γ (see Extended Data Fig. 3 for gating 
strategy). Moreover, coexpression of IL-2 and TNF-α was analyzed to characterize 
cytokine expression profiles. Reactive CD4 and CD8 T cell levels after control 
stimulations were subtracted from those obtained after SARS-CoV-2-specific 
stimulation, and 0.03% of reactive T cells was set as the detection limit based on the 
distribution of T cell frequencies after control stimulations.
Determination of SARS-CoV-2-specific antibodies and neutralization 
capacity. SARS-CoV-2-specific IgG antibodies towards the receptor binding 
domain of SARS-CoV-2 spike protein were quantified using an enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s instructions 
(SARS-CoV-2-QuantiVac, Euroimmun). Antibody binding units (BAU ml–1)  
<25.6 were scored negative, ≥25.6 and <35.2 were scored intermediate and 
≥35.2 were scored positive. SARS-CoV-2-specific IgGs towards the N protein 
were quantified using ELISA according to the manufacturer´s instructions 
(Anti-SARS-CoV-2-NCP-ELISA, Euroimmun). Antibody levels are calculated  
as ratios defined as the extinction of the patient sample divided by the extinction  
of a calibrator serum. Ratios ≥1.1 were scored positive. A neutralization assay  
based on antibody-mediated inhibition of soluble ACE2 binding to the  
plate-bound S1 receptor binding domain was used at a single serum dilution 
according to the manufacturer’s instructions (SARS-CoV-2-NeutraLISA, 
Euroimmun). Surrogate neutralizing capacity was calculated as percentage of 
inhibition (IH) by 1 minus the ratio of the extinction of the respective sample  
and the extinction of the blank value. IH < 20% was scored negative, IH ≥ 20 to 
<35 intermediate and IH ≥ 35% positive.
Statistical analysis. Kruskal–Wallis testing, followed by Dunn’s multiple 
comparisons test, was performed to compare unpaired nonparametric data 
between groups (lymphocyte subpopulations, T cell and antibody levels). Data with 
normal distribution were analyzed using ordinary one-way analysis of variance 
(cytokine expression profiles, age). Categorial analyses on gender and adverse 
events were performed using the X2 test. Correlations between levels of T cells, 
antibodies and plasmablasts were analyzed according to Spearman, and P < 0.05 
was considered statistically significant. Analysis was carried out using GraphPad 
Prism 9.0 software using two-tailed tests. Cytokine profiles were plotted using the 
VennDiagram package (v.1.6.20)21 running under R (v.4.0.2).
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Figures 1 and 2 and Extended Data Figs. 2 and 4–7 have associated raw data.  
The data that support the findings of this study are available from the 
corresponding author upon request, and data are available in a public repository 
(https://doi.org/10.5281/zenodo.5080642). Because age and the individual 
assignment of the mRNA vaccine (BNT162b2 or mRNA-1273) may be subject  
to confidentiality, data in the repository refer to age groups, and mRNA vaccines 
are not specified individually.
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Extended Data Fig. 1 | Study design. Time between first and second vaccination and the time between second vaccination and analysis is shown for the 
three vaccination regimens (homologous ChAdOx1 nCoV-19 vector vaccination (V/V, n = 55), heterologous ChAdOx1 nCoV-19 vector/mRNA vaccination 
(V/mRNA, n = 97) or homologous mRNA vaccination (mRNA/mRNA, n = 64). #3 individuals were excluded from further analysis due to IgG positivity in a 
SARS-CoV-2 nucleocapsid ELISA.
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Extended Data Fig. 2 | Demographic and clinical characteristics of the study population. Demographic characteristics and vaccine-related data are 
shown for the three vaccination regimens (homologous ChAdOx1 nCoV-19 vector vaccination (V/V, n = 55), heterologous ChAdOx1 nCoV-19 vector/
mRNA vaccination (V/mRNA, n = 96) or homologous mRNA vaccination (mRNA/mRNA, n = 62)). In addition, information on differential blood counts 
and on lymphocyte subpopulations is provided.
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Extended Data Fig. 3 | Representative analysis of spike- and SeB-reactive CD4 and CD8 T cells. Lymphocytes were identified among total events 
by backgating of CD4 and/or CD8 positive cells combined with signals for size (FSC) and granularity (SSC). Hight and area signals of FSC were used 
to exclude doublets. CD4 T cells were identified among single cells by CD4 positive and CD8 negative signals. Likewise, CD8 T cells were defined as 
T cells being CD8 positive and CD4 negative. In (b) and (c) representative contour plots of CD4 and CD8 T cells of a 37-year-old female are shown after 
antigen-specific stimulation with SARS-CoV-2 spike peptides or respective control stimuli for negative (DMSO) or positive control (SEB) stimulation. 
Numbers indicate percentages of CD4 or CD8 T cells co-expressing the activation marker CD69 and the cytokines IFN-γ, IL-2 and/or TNF-α. FSC, forward 
scatter; IFN, interferon; IL, interleukin; SEB, Staphylococcus aureus enterotoxin B; SSC, side scatter; TNF, tumor necrosis factor.
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Extended Data Fig. 4 | SARS-CoV-2 spike-specific T cells producing TNF-α and IL-2 after vaccination with homologous and heterologous prime-booster 
regimens. Percentages of SARS-CoV-2 spike-specific CD4 and CD8 T cells were determined after antigen-specific stimulation of whole blood samples 
followed by intracellular cytokine analysis using flow-cytometry. Reactive cells were identified by co-expression of the activation marker CD69 and the 
cytokine tumor necrosis factor (TNF) α (left panel), interleukin 2 (IL-2, middle panel), or any of the cytokines analyzed (IFN-γ/TNF-α/IL-2, right panel), 
respectively, among CD4 or CD8 T cells and subtraction of background reactivity of respective negative control stimulations. T cell responses were 
compared between individuals who either received SARS-CoV-2 vector/vector (V/V, n = 55), vector/mRNA (V/mRNA, n = 96) or mRNA/mRNA vaccines 
(mRNA/mRNA, n = 62) using two-sided Kruskal-Wallis test with Dunn’s multiple comparisons post test. Bars represent medians with interquartile ranges, 
individuals who received the mRNA-1273 vaccine are indicated by grey symbols.
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Extended Data Fig. 5 | See next page for caption.
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Extended Data Fig. 5 | Gating strategy and analysis of spike-specific cytokine-expression profiles. (a) To characterize spike- and SEB-reactive CD4 
T cells regarding their single or combined expression of the cytokines IFN-γ, IL-2, and TNF-α, CD4 T cells positive for combined expression of CD69 
and IFN-γ were divided into four subpopulations according to additional expression of IL-2 and TNF-α. Using NOT Boolean Gating, all CD4 T cells 
which were not CD69 + IFN-γ + were analyzed for CD69 + IL-2+ and CD69 + TNF-α + CD4 T cells. Using OR Boolean Gating, CD69 + IL-2+ and/or 
CD69 + TNF-α + CD4 T cells were divided into IL-2 single, TNF-α single or IL-2+TNF-α + cells. After subtraction of background reactivity from negative 
control stimulations, the sum of these 7 subpopulations was set to 100%. A similar strategy was applied for CD8 T cells. (b) Cytokine-expression profiles 
of spike-specific CD4 and CD8 T cells in all individuals showing single or combined expression of the cytokines IFN-γ, interleukin (IL) 2 and tumor necrosis 
factor (TNF) α. To allow for robust statistics, analysis was restricted to samples with at least 30 cytokine-positive T cells (n = 178 for CD4 and n = 112 for 
CD8 T cells). Numbers refer to the percentage of cells expressing the respective cytokine. IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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Extended Data Fig. 6 | Cytokine-expression profiles of SeB-reactive CD4 and CD8 T cells after vaccination with homologous and heterologous 
prime-booster regimens. Cytokine expression of CD4 (a) and CD8 T cells (b) after stimulation with Staphylococcus aureus enterotoxin B (SEB), was 
compared between individuals who either received SARS-CoV-2 vector/vector (V/V), vector/mRNA (V/mRNA), or mRNA/mRNA vaccine combinations. 
Cytokine-expressing T-cells were divided into 7 subpopulations according to their expression of IFN-γ, IL-2, and TNF-α (single, double or triple 
cytokine-expressing cells, for gating strategy, see Extended Data Fig. 5). Only samples of the study participants included in Fig. 1f are displayed (at least 
30 cytokine-expressing CD4 or CD8 T-cells, respectively, after spike-specific stimulation, n = 31 and n = 15 for V/V, n = 89 and n = 73 for V/mRNA and 
n = 58 and n = 24 for mRNA/mRNA vaccine regimes). Differences among subpopulations between the groups were determined using ordinary one-way 
ANOVA test. Bars represent means and standard deviations of subpopulations among all SEB-reactive CD4 and CD8 T cells, respectively. IFN, interferon, 
IL, interleukin, TNF, tumor necrosis factor.
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Extended Data Fig. 7 | Immune responses against the SARS-CoV-2 spike protein after vaccination with homologous and heterologous prime-booster 
regimens in age-matched subgroups. Immune responses were compared between age-matched subgroups of 50 individuals each who either received 
homologous ChAdOx1 nCoV-19 vector vaccination (V/V, mean age 47.0 ± 11.2 years, 33 females), heterologous ChAdOx1 nCoV-19 vector/mRNA 
vaccination (V/mRNA, 47.1 ± 9.2 years, 38 females) or homologous mRNA vaccination (mRNA/mRNA, 46.4 ± 11.5 years, 35 females, p = 0.940). 
Spike-specific IgG-levels (a) and neutralizing antibodies (b) were quantified by ELISA and a surrogate neutralization assay and compared between groups. 
Percentages of SARS-CoV-2 spike-specific (c) and SEB-reactive (d) CD4 and CD8 T cells were determined after antigen-specific stimulation of whole 
blood samples followed by intracellular cytokine analysis using flow-cytometry. Reactive cells were identified by co-expression of CD69 and the cytokine 
interferon (IFN) γ among CD4 or CD8 T cells and subtraction of background reactivity of respective negative control stimulations. Bars represent medians 
with interquartile ranges. Individuals who received the mRNA-1273 vaccine are indicated by grey symbols (9 in the homologous mRNA/mRNA group). 
Differences between the groups were calculated using two-sided Kruskal-Wallis test with Dunn´s multiple comparisons post test. Dotted lines indicate 
detection limits for antibodies in (a) and (b), indicating negative, intermediate and positive levels or levels of inhibition, respectively as per manufacturer’s 
instructions, and detection limits for SARS-CoV-2-specific CD4 T cells in (c) and (d). SEB, Staphylococcus aureus enterotoxin B.
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